Cefixime Capsules — Class II drug recall D-0359-2022
Terminated recall by Ascend Laboratories, LLC, reported 2022-01-12, distributed nationwide. Failed impurities/degradation specifications
| Recall number | D-0359-2022 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Ascend Laboratories, LLC, Parsippany, NJ, United States |
| Recall initiated | 2021-12-21 |
| Classified | 2022-01-05 |
| Reported by FDA | 2022-01-12 |
| Terminated | 2023-04-13 |
| Distributed | Nationwide (US) |
| Quantity | 42,698 bottles |
| Reason classes | specification failure |
| NDC | 67877-0584, 67877-0584-01, 67877-0584-05, 67877-0584-33, 67877-0584-50 |
| Lot numbers | 20140293, 20141525, 20141526, 20141527, 20143019, 20143020, 20143021, 20143022, 20144759, 20144760, 20144761 |
| Expiration dates | 2021-12-20, 2022-03-20, 2022-07-20 |
Product
Cefixime Capsules, 400 mg, 50-count bottles, Rx only, Manufactured by: Alkem Laboratories Ltd., Mumbai, India, Distributed by: Ascend Laboratories, LLC, Parsippany, NJ, NDC 67877-584-50
Reason for recall
Failed impurities/degradation specifications
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0359-2022. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.